Advertisement

The Innovation System for Leishmaniasis Therapy in Brazil

  • Mady Barbeitas
Chapter

Abstract

The lack of innovation in the field of neglected tropical diseases has been extensively documented. Nevertheless, few papers investigate the advances in this field. The focus of this chapter is to reveal the new actors and innovative mechanisms, such as public–private partnerships, created to encourage the development of new therapies for leishmaniases in Brazil in the year 2012. Leishmaniases have a large spectrum of clinical manifestations, the two main forms being visceral and cutaneous leishmaniasis (hereafter VL and CL respectively). CL is one of the most serious skin diseases in developing countries, while VL is the leading cause of parasite-related deaths after malaria. On the basis of qualitative fieldwork, I analyze the efforts and projects of an international NGO, Drugs for Neglected Diseases Initiative (DNDi), executed in collaboration with Brazilian institutions. The main argument is that DNDi is capable of providing long-term solutions for leishmaniases because it creates multilateral projects of cooperation with governments and public institutions in order to support the technological development in the South. These projects are part of the new geography of innovation, narrowing the technological dependency on the North regarding diseases that have a particular impact on people in the low- and middle-income countries.

Bibliography

  1. Alonso, L. M. (2008). Informe de reunión de coordinadores de programa nacional de leishmaniasis, Medellín, Colombia.Google Scholar
  2. Barreto, M. L., et al. (2011, May 28). Successes and failures in the control of infectious diseases in Brazil: Social and environmental context, policies, interventions, and research needs. The Lancet, 377, 1877–1889.CrossRefGoogle Scholar
  3. Boechat, N. (2007). O desenvolvimento tecnológico em síntese orgânica em Farmanguinhos, EniFarMed, São Paulo. http://site.protec.org.br/arquivos/galeria/N%C3%BAbiaBoechatfiocruz.pdf. Accessed 6 May 2013.
  4. Bonah, C. (2005). Les agents thérapeutiques. Paradoxes et ambiguïtés d’une histoire des remèdes aux XIXe et XXe siècles. In Histoire et médicament aux XIXe et XXe siècles. Paris: Editions Glyphe.Google Scholar
  5. Bradol, J.-H., & Vidal, C. (2009). Innovations médicales en situations humanitaires. Le travail de Médecins sans Frontières. Paris: L’Harmattan.Google Scholar
  6. Cassier, M., & Correa, M. (2009). Éloge de la copie: le reverse engineering des antirétroviraux contre le VIH Sida dans les laboratoires pharmaceutiques brésiliens. Sciences Sociales et Santé, 27(3), 77–103.CrossRefGoogle Scholar
  7. Clinical Trials: Efficacy and safety study of drugs for treatment of visceral leishmaniasis in Brazil (LVBrasil). http://clinicaltrials.gov. Accessed 10 July 2012.
  8. Correa, S. (2013). O ‘combate’ às doenças tropicais na impresa colonial alemã. História, Ciências, Saúde – Manguinhos, Rio de Janeiro, 20(1), 69–91.CrossRefGoogle Scholar
  9. Debue-Barazer, C. (2007). Les implications scientifiques et industrielles du succès de la Stovaïne®. Ernest Fourneau (1872–1949) et la chimie des médicaments en France. Gesnerus, 64, 24–53.Google Scholar
  10. Dedet, J.-P. (1999). Les leishmanioses. Paris: ELLIPSES.Google Scholar
  11. DNDi. (2011a). Un modelo Colaborativo de I+D para las enfermidades olvidadas, portifolio de I+D.Google Scholar
  12. DNDi. (2011b, September). Business plan 2011–2018.Google Scholar
  13. FIOCRUZ. (2011, October). Agência Fiocruz de notícia, revista de Manguinhos, Saúde na Tela. Atenção às doenças negligenciadas e de alto custo. http://www.fiocruz.br/ccs/media/rev23_doencasnegligenciadas.pdf
  14. Gilles, H. M., & Lucas, A. O. (1998). Tropical medicine: 100 years of progress. British Medial Bulletin, 54(2), 269–280.CrossRefGoogle Scholar
  15. Global Forum for Health Research. (2000). The 10/90 report on health research. http://www.globalforumhealth.org. Accessed 4 June 2015.
  16. Lachenal, G. (2014). Le médicament qui devait sauver l’Afrique. Un scandale pharmaceutique aux colonies. Paris: La découverte.Google Scholar
  17. Les Maladies Tropicales, la Société de Pathologie Exotique et l’Institut Pasteur: un partenariat qui a plus de cent ans. http://www.pathexo.fr/documents/centenaire/centenaire-0-dautry.pdf. Accessed 5 Mar 2016.
  18. Liese, B., et al. (2010). Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. The Lancet, 375, 67–76.CrossRefGoogle Scholar
  19. Löwy, I. (2006). Virus, mosquitos e modernidade: a febre amarela no Brasil entre ciência e política. Rio de Janeiro: Editora Fiocruz.CrossRefGoogle Scholar
  20. Matlashewski, G., et al. (2011). Visceral leishmaniasis: Elimination with existing interventions. The Lancet, 11, 322–325.CrossRefGoogle Scholar
  21. Médecins Sans Frontières. (2012, June 15). Maladies tropicales négligées: Sortir de l’oubli, Rapports/dossiers. http://www.msf.fr/actualite/publications/sortir-oubli. Accessed 8 Oct 2012.
  22. Médecins Sans Frontières and Drugs for Neglected diseases Working Group. (2001). Fatal imbalance: The crisis in research and development for drugs for neglected diseases. Geneva: Médecins Sans Frontières Access to Essential Medicines Campaign and the Drugs for Neglected Diseases Working Group.Google Scholar
  23. Ministry of Health. (2006). Manual de vigilancia da leishmaniose visceral. Brasília: Editora do Ministério da Saúde.Google Scholar
  24. Ministry of Health. (2007). Manual de vigilancia da leishmaniose tegumentar americana. Brasília: Editora do Ministério da Saúde.Google Scholar
  25. Ministry of Health, Secretariat of Science, Technology and Strategic Inputs. (2010). Department of Science and Technology. Decit 10 years. Brasília. http://bvsms.saude.gov.br/bvs/publicacoes/decit_10anos.pdf. Accessed 31 May 2015.
  26. Monnais, L. (2009). From colonial medecines to global pharmaceuticals ?: The introduction of sulfa drugs in French Vietnam. East Asian Science, Technology and Society: An International Journal, 3(2&3), 257–285.CrossRefGoogle Scholar
  27. Moon, S., et al. (2011). A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization and Health 7, 39. www.globalisationhealth.com/content/7/1/39CrossRefGoogle Scholar
  28. Neill, D. (2009). Paul Ehrlich’s colonial connections: Scientific networks and sleeping sickness drug therapy research, 1900–1914. Social History of Medicine, 22(1), 61–77.CrossRefGoogle Scholar
  29. PAHO/WHO, Brazilian office. (1998). A saúde no Brasil.Google Scholar
  30. Pécoul, B., et al. (1999). Access to essential drugs in poor countries. A lost battle? JAMA, 281(4), 361–367.CrossRefGoogle Scholar
  31. Pignarre, P. (2004). Le grand secret de l’industrie pharmaceutique. Paris: La découverte.Google Scholar
  32. Pinheiro, A. Z. (2004) Gestão de programas horizontais: o caso do Programa de Desenvolvimento Tecnológico em Insumos para a Saúde (PDTIS) da FIOCRUZ. National School of Public Health Sérgio Arouca, FIOCRUZ, Rio de Janeiro.Google Scholar
  33. Portal Brasil, Governo Brasileiro, Saúde. http://www.brasil.gov.br/sobre/saude/orgaos-vinculados/fiocruz. Accessed 5 Sept 2012.
  34. Posada, M., et al. (2008). Enfermedades raras. Concepto, epidemiología y situación actual en España. Anales del Sistema Sanitario de Navarra, 31(Suppl. 2), 9–20.Google Scholar
  35. Repères chronologiques de la Société de Pathologie Exotique. http://webext.pasteur.fr/archives/spe0.html. Accessed 5 Mar 2016.
  36. Sackett, D. L., et al. (1996). Evidence-based medicine: What it is and what it isn’t. BMJ, 312, 71–72.CrossRefGoogle Scholar
  37. Trindade, E. M. C. (2001). Modèles et emprunts: l’hygiénisme au Brésil (fin XIXe – début XXe siècles). In Les hygiénistes: enjeux, modèles et pratiques (pp. 267–295). Paris: Editions Belin.Google Scholar
  38. Trouiller, P., et al. (2002). Drug development for neglected diseases: A deficient market and a public-health policy failure. The Lancet, 359, 885.CrossRefGoogle Scholar
  39. Vale, E. C. S., & Furtado, T. (2005). Leishmaniose tegumentar no Brasil: revisão histórica da origem expansão e etiologia. Anais Brasileiros de Dermatologia, 80(4), 421–428.CrossRefGoogle Scholar
  40. WHO. Control of the leishmaniases: Report of a meeting of the WHO expert committee on the control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series; no. 949.Google Scholar
  41. WHO report of the commission on macroeconomics and health: “Macroeconomics and health: Investing in health for economic development” 2001.Google Scholar
  42. Wilkinson, L., & Power, H. (1998). The London and Liverpool Schools of Tropical Medicine 1898–1998. British Medical Bulletin, 54(2), 281–292.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Authors and Affiliations

  • Mady Barbeitas
    • 1
  1. 1.CERMES3-EHESSParisFrance

Personalised recommendations